Pralsetinib in patients (pts) with advanced or metastatic RET-altered thyroid cancer (TC): Updated data from the ARROW trial.

Aaron Scott  Mansfield

Honoraria - Roche

Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst)

Research Funding - Novartis (Inst)

Travel, Accommodations, Expenses - Abbvie; Roche

Vivek  Subbiah

Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm

Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)

Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar

Other Relationship - Medscape

Martin H.  Schuler

Honoraria - Amgen; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen-Cilag; Novartis

Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; GlaxoSmithKline; Merck Serono; Novartis; Roche; Sanofi; Takeda

Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)

Patents, Royalties, Other Intellectual Property - Highly sensitive method for mutation detection by PCR (Inst)

Viola Weijia  Zhu

Employment - Nuvalent, Inc.

Stock and Other Ownership Interests  - Nuvalent, Inc.; TP Therapeutics; TP Therapeutics (I)

Honoraria - AstraZeneca; BeiGene; Blueprint Medicines; Roche/Genentech; Takeda; Xcovery

Consulting or Advisory Role - AstraZeneca; BeiGene; Roche/Genentech; Takeda; TP Therapeutics; Xcovery

Speakers' Bureau - AstraZeneca; Blueprint Medicines; Roche/Genentech; Takeda

Travel, Accommodations, Expenses - AstraZeneca; Roche/Genentech; Takeda; TP Therapeutics

Julien  Hadoux

No Relationships to Disclose

Marcia S.  Brose

Honoraria - Bayer; Eisai; Lilly

Consulting or Advisory Role - Bayer; Blueprint Medicines; Eisai; Exelixis; Lilly; Loxo

Research Funding - Bayer (Inst); Blueprint Medicines (Inst); Eisai (Inst); Exelixis (Inst); Lilly (Inst); Loxo (Inst)

Giuseppe  Curigliano

Honoraria - Ellipses Pharma

Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Daichi-Sankyo; Foundation Medicine; GlaxoSmithKline; Guardant Health; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen

Speakers' Bureau - Daiichi Sankyo; Foundation Medicine; Lilly; Novartis; Pfizer; Roche/Genentech; Samsung; Seagen

Research Funding - Merck (Inst)

Travel, Accommodations, Expenses - Pfizer; Roche/Genentech

Lori J.  Wirth

Consulting or Advisory Role - Bayer; Blueprint Medicines; Coherus Biosciences; Eisai; Exelixis; Lilly; Loxo; Merck; Morphic Therapeutic

Research Funding - Ayala Pharmaceuticals (Inst); Checkmate Pharmaceuticals (Inst); CUE Biopharma (Inst); Eisai (Inst); Lilly (Inst)

Expert Testimony - Eisai

Other Relationship - PDS Biotechnology

Elena  Garralda

Consulting or Advisory Role - Alkermes; Anaveon; Boehringer Ingelheim; Bristol-Myers Squibb; Ellipses Pharma; F-Star Therapeutics; Hengrui Therapeutics; Janssen; MAB Discovery; NeoMed; Roche; Seagen; Thermo Fisher Scientific

Speakers' Bureau - Lilly; MSD; Novartis; Roche; Thermo Fisher Scientific

Research Funding - AstraZeneca/MedImmune (Inst); BeiGene (Inst); Novartis (Inst); Roche (Inst); Taiho Oncology (Inst); Thermo Fisher Scientific (Inst)

Other Relationship - Affimed Therapeutics (Inst); Amgen (Inst); Anaveon (Inst); AstraZeneca (Inst); BioNTech (Inst); Catalym (Inst); CytomX Therapeutics (Inst); F-Star Beta Limited (Inst); F. Hoffmann LaRoche (Inst); Genentech (Inst); Genmab (Inst); Hutchison MediPharma (Inst); Imcheck Therapeutics (Inst); Immunocore (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Merck KGaA (Inst); Novartis (Inst); Peptomyc (Inst); Ribon Therapeutics (Inst); Roche (Inst); Seagen (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst)

Douglas  Adkins

Consulting or Advisory Role - Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Coherus Biosciences; CUE Biopharma; Eisai Europe; Exelixis; Immunitas; Kura Oncology; Merck; TargImmune Therapeutics; twoXAR; Vaccinex; Xilio Therapeutics

Research Funding - Aduro Biotech (Inst); AstraZeneca (Inst); BeiGene (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Cofactor Genomics (Inst); CUE Biopharma (Inst); Debiopharm Group (Inst); Epizyme (Inst); Exelixis (Inst); Gilead Sciences (Inst); Hookipa Biotech (Inst); Immutep (Inst); Innate Pharma (Inst); ISA Pharmaceuticals (Inst); Kura Oncology (Inst); Lilly (Inst); Matrix Biomed (Inst); MedImmune (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Rubius Therapeutics (Inst); Sensei Biotherapeutics (Inst); Shanghai Denovo (Inst); Vaccinex (Inst)

Yann  Godbert

Honoraria - Bayer; Eisai Europe; Lilly

Travel, Accommodations, Expenses - Eisai Europe

Myung-Ju  Ahn

Honoraria - Amgen; AstraZeneca; Lilly; Merck Serono; MSD; TAKEDA; YUHAN

Consulting or Advisory Role - Alpha pharmaceutical; Amgen; AstraZeneca; Lilly; Merck Serono; MSD; Pfizer; TAKEDA; YUHAN

Research Funding - YUHAN

Philippe Alexandre  Cassier

Honoraria - Amgen; ITeos Therapeutics; Janssen

Consulting or Advisory Role - OSE Immunotherapeutics

Research Funding - Abbvie (Inst); AstraZeneca (Inst); Bayer (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); GlaxoSmithKline (Inst); Innate Pharma (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Plexxikon (Inst); Roche/Genentech (Inst); Taiho Pharmaceutical (Inst); Toray Industries (Inst); Transgene (Inst)

Travel, Accommodations, Expenses - Amgen; AstraZeneca/MedImmune; Merck Serono; Merck Sharp & Dohme; Netris Pharma; Roche

Byoung Chul  Cho

Leadership - Interpark Bio; J Ints Bio

Stock and Other Ownership Interests  - Bridgebio; Cyrus therapeutics; Gencurix; Interpark Bio; Kanaph Therapeutics; Theravance

Consulting or Advisory Role - AstraZeneca; Blueprint medicines; Boehringer Ingelheim; Bridgebio; Bristol-Myers Squibb; Cyrus therapeutics; Guardant Health; J INTS BIO; Janssen; Kanaph Therapeutics; Lilly; Medpacto; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda; Yuhan

Research Funding - Abbvie; AstraZeneca; Bayer; Blueprint medicines; Champions Oncology; Dizal Pharma; Dong-A ST; GI Innovation; Interpark Bio; Janssen; Lilly; Medpacto; Mogam Biotechnology Research Institue; MSD; Novartis; Ono Pharmaceutical; Yuhan

Patents, Royalties, Other Intellectual Property - Champions Oncology

Other Relationship - DAAN Biotherapeutics

Chia-Chi  Lin

Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche

Consulting or Advisory Role - Abbvie; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis; PharmaEngine

Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis

Hui  Zhang

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Alena  Zalutskaya

Employment - Blueprint Medicines

Stock and Other Ownership Interests  - Blueprint Medicines

Teresa  Barata

Employment - Roche

Stock and Other Ownership Interests  - Roche

Astrid  Scalori

Employment - Roche

Stock and Other Ownership Interests  - Roche

Matthew H.  Taylor

Honoraria - Bayer; Bristol Myers Squibb Foundation; Eisai; Merck; Pfizer; Regeneron; Roche

Consulting or Advisory Role - Array BioPharma; Bayer; Blueprint Medicines; Bristol-Myers Squibb; Eisai; Loxo; Novartis; Sanofi

Speakers' Bureau - Blueprint Medicines; Bristol-Myers Squibb; Eisai; Merck

Research Funding - Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Loxo/Bayer (Inst); Merck (Inst); Moderna Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)